Theriva Biologics said it has dosed the first patient with VCN-01 in the Phase 2a VIRAGE2 trial, a study evaluating repeated dosing of its systemically administered oncolytic adenovirus in newly diagnosed metastatic pancreatic ductal adenocarcinoma. The move advances the company’s development plan alongside standard-of-care chemotherapy with gemcitabine and nab-paclitaxel, with Theriva targeting initial pharmacodynamic and safety readouts in the third quarter of 2027.
Theriva shares closed Thursday at $0.22, down 0.13%. Over the past year, the stock has traded in a wide range between $0.16 and $0.86, underscoring the high expectations and uncertainty typically associated with early-stage clinical milestones.
Key takeaways
- Stock move: Theriva Biologics shares closed Thursday at $0.22, down 0.13%.
- Catalyst: The company announced dosing of the first patient in the Phase 2a VIRAGE2 study of VCN-01 in metastatic pancreatic cancer.
- What the trial tests: Repeated dosing of VCN-01 combined with gemcitabine/nab-paclitaxel in first-line metastatic PDAC.
- Implication for investors: Data on safety and viral genome exposure are expected in 2027, with potential relevance for a future Phase 3 strategy.
What drove the announcement
Theriva’s update centers on progress in the Phase 2a VIRAGE2 trial, which is designed to evaluate more frequent administration of VCN-01 alongside standard-of-care chemotherapy. The study enrolls patients with first-line metastatic pancreatic ductal adenocarcinoma receiving gemcitabine/nab-paclitaxel.
VCN-01 (zabilugene almadenorepvec) is intended to attack rapidly replicating tumor cells through oncolytic activity. The therapy is also engineered to degrade tumor stroma, which can function as both a physical barrier and an immunosuppressive environment within pancreatic tumors—an important consideration given the disease’s resistance to many treatment approaches.
The Phase 2a program builds on outcomes from the company’s earlier Phase 2b VIRAGE study. According to Theriva, the VIRAGE results showed improved overall survival, progression-free survival, and duration of response when VCN-01 was combined with gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy alone.
Following those findings, and based on feedback from the U.S. FDA and the European Medicines Agency, Theriva is adjusting the dosing approach in VIRAGE2. The company is evaluating at least three doses at roughly two-month intervals to potentially strengthen clinical outcomes and generate data supportive of later-stage testing.
How VIRAGE2 is structured
VIRAGE2 is a single-arm, open-label study enrolling six patients newly diagnosed with metastatic PDAC in Spain. The company said the study will assess administering at least three doses of VCN-01 together with gemcitabine/nab-paclitaxel, spaced at approximately two-month intervals.
Theriva’s focus for the trial includes both exposure-related measures and clinical activity signals. The primary endpoints are safety and VCN-01 viral genome levels in blood, while secondary endpoints include objective response rate, duration of response, progression-free survival, overall survival, and anti-VCN-01 neutralizing antibody levels.
The inclusion of neutralizing antibody assessment reflects a key development question for systemic viral therapies: whether immune responses against the vector could limit repeated dosing exposure or efficacy.
Market reaction and what it signals
While the announcement is a substantive clinical milestone—first patient dosing in a trial intended to support a potential Phase 3 path—Theriva shares finished Thursday slightly lower. The modest move is consistent with how early biotech stocks often trade around protocol-level updates: investors may view the dosing start as progress, but may still be waiting for the more decision-relevant safety and pharmacodynamic data.
Given the broad one-year trading range, the stock’s reaction suggests market participants are balancing encouragement from moving into patient dosing against the timelines and binary nature of clinical trial results, especially in metastatic pancreatic cancer where prior therapies have faced steep challenges.
Bigger picture: timeline and upcoming catalysts
Theriva expects to complete enrollment in the second half of 2026. The company anticipates initial pharmacodynamic and safety, tolerability data readout by the third quarter of 2027.
Investors will likely watch for several items as the trial proceeds: whether viral genome levels in blood confirm consistent exposure with repeated dosing, the extent of any treatment-emergent safety signals when combined with gemcitabine/nab-paclitaxel, and early indications that dosing frequency can sustain anti-tumor activity without being undermined by neutralizing antibodies.
With enrollment not expected to conclude until 2026 and key initial data not due until 2027, the next major catalysts for Theriva appear tied to ongoing trial execution and subsequent interim updates on dosing progress, patient tolerability, and pharmacodynamic readouts.
